(Q43676412)

English

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen (English)

1 reference

Europe PubMed Central

25 November 2017

interferon alfa

1 reference

based on heuristic

inferred from title

author name string

R V Smalley

1

1 reference

Europe PubMed Central

25 November 2017

E Weller

2

1 reference

Europe PubMed Central

25 November 2017

M J Hawkins

3

1 reference

Europe PubMed Central

25 November 2017

M M Oken

4

1 reference

Europe PubMed Central

25 November 2017

M J O'Connell

5

1 reference

Europe PubMed Central

25 November 2017

S Haase-Statz

6

1 reference

Europe PubMed Central

25 November 2017

E C Borden

7

1 reference

Europe PubMed Central

25 November 2017

publication date

1 July 2001

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

15

1 reference

Europe PubMed Central

25 November 2017

7

1 reference

Europe PubMed Central

25 November 2017

1118-1122

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402161

0 references

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402161

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402161

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43676412&oldid=2102434851"